One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
High-priority historical-source disagreement. Large pre/post-HD doses and per-dose versus per-day wording are retained exactly in meaning to expose the original discrepancy, not endorsed as a current regimen. Use a current indication-specific source before prescribing.
NIH PCP treatment and Nebraska specialist alternatives at very low kidney function are not the same as the manufacturer general not-recommended restriction. Doses expressed as mg/kg refer to trimethoprim, not combined TMP-SMX mass.
The oral mirror expresses renal adjustment as a proportion of the indication-specific regimen. Renal impairment also increases potassium-monitoring relevance.
What to reconcile: Review indication, trimethoprim amount, potassium and interactions. Do not generate an IV or Pneumocystis regimen from this fraction alone.
Open this note and its source referencesFor PCP treatment in adults/adolescents with HIV, the baseline is TMP 5 mg/kg IV every 6-8 hours or two double-strength tablets orally every 8 hours.
| Renal adjustment | PCP treatment |
|---|---|
| 15-30 mL/min | TMP 5 mg/kg IV every 12 hours or two DS tablets every 12 hours |
| <15 mL/min | TMP 5 mg/kg IV daily, or one DS tablet every 12 hours (alternative: two DS daily) |
| Intermittent HD | TMP 5 mg/kg IV daily or two DS tablets daily; administer after HD on dialysis days |
NIH suggests considering TMP-level monitoring, targeting 5-8 mcg/mL. This is a PCP-specific expert regimen, not the manufacturer's general <15 not-recommended restriction, and not a CRRT/PD protocol. All weight-based doses refer to trimethoprim, not combined ingredient mass.
RDM30-101-tmp-smx-1 · Source locator: NIH OI table - PCP treatment in renal insufficiency; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=tmp-smx&s1=RDM30-101-tmp-smx&h1=de9799ba85abc398e5bba7c441d82abe40700e3d15ac5b9a6ed17e6b939be206